What does this research mean for the field?

In AML patients receiving allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide GVHD prophylaxis, utilizing donors aged 20-44 years significantly reduces relapse risk and improves leukemia-free and overall survival compared to donors aged 45 years or older. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the impact of donor age on outcomes for AML patients undergoing alloHCT with PTCy-based GVHD prophylaxis.

May 29, 2026Journal of Clinical Oncology

Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.

View Full Paper

Ask AI

Bookmark

Authors

JBJohn Behman MAMuhammad Bilal Abid

Discussion

Member takes

Overview

Randomized trial shows that younger donor age improves outcomes in AML patients, indicating better donor selection is needed.

Key Points

To evaluate the impact of donor age on outcomes for AML patients undergoing alloHCT with PTCy-based GVHD prophylaxis.
Analyzed data from CIBMTR dataset for AML patients receiving alloHCT between 2017-2021 with PTCy prophylaxis.
Excluded patients with primary induction failure or relapsed disease at transplant.
Conducted univariate and multivariate analyses on 5,702 identified patients.
CI of relapse at 24 months was 36.4% for donors aged ≥45 years vs 30.1%-32.9% for younger donors, p=0.003.
Overall survival at 24 months was 45.9% for older donors vs 55.4%-58.5% for younger donors, p<0.001.
Multivariable analysis showed significantly reduced relapse and improved survival rates for donors aged 20-44 years compared to those ≥45 years.

Cite This Study

Behman et al. (2026) studied this question.

synapsesocial.com/papers/6a192f07fab5b468c44185ca https://doi.org/10.1200/jco.2026.44.16_suppl.6564

View Full Paper

Ask AI

Bookmark

May 29, 2026Journal of Clinical Oncology

Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.

View Full Paper

Ask AI

Bookmark

Authors

JBJohn Behman MAMuhammad Bilal Abid

Discussion

Member takes

Overview

Randomized trial shows that younger donor age improves outcomes in AML patients, indicating better donor selection is needed.

Key Points

To evaluate the impact of donor age on outcomes for AML patients undergoing alloHCT with PTCy-based GVHD prophylaxis.
Analyzed data from CIBMTR dataset for AML patients receiving alloHCT between 2017-2021 with PTCy prophylaxis.
Excluded patients with primary induction failure or relapsed disease at transplant.
Conducted univariate and multivariate analyses on 5,702 identified patients.
CI of relapse at 24 months was 36.4% for donors aged ≥45 years vs 30.1%-32.9% for younger donors, p=0.003.
Overall survival at 24 months was 45.9% for older donors vs 55.4%-58.5% for younger donors, p<0.001.
Multivariable analysis showed significantly reduced relapse and improved survival rates for donors aged 20-44 years compared to those ≥45 years.

Cite This Study

Behman et al. (2026) studied this question.

synapsesocial.com/papers/6a192f07fab5b468c44185ca https://doi.org/10.1200/jco.2026.44.16_suppl.6564

View Full Paper

Ask AI

Bookmark